HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Clinical assessment of paucibacillary leprosy under multidrug therapy-three years followup study.

Abstract
408 skin smear negative paucibacillary leprosy cases who had completed six months MDT were kept under surveillance for three years. The clinical assessment at the end of surveillance showed that 276 (82%) of all the cases attained inactivity. Two patients who were inactive showed signs of relapse. Five patients showed more activity though they were regressing under treatment. The inactivity rate was much higher amongst the patients with 1 to 3 skin lesions (88%) as compared to the patients with greater than or equal to 4 lesions (60%). The difference was statistically significant (P less than 0.001). The past treatment before MDT did not appear to influence the clinical course of the disease. 17% of the patients essentially border-line type continued to show signs of activity even after 3 years surveillance indicating the need for triple drug therapy (to be treated as multibacillary). However large scale data on relapse rate would be essential before the efficacy of WHO short-term therapy for paucibacillary leprosy is evaluated.
AuthorsC R Revankar, V G Karjivkar, V J Gurav, R Ganapati
JournalIndian journal of leprosy (Indian J Lepr) Vol. 61 Issue 3 Pg. 355-9 (Jul 1989) ISSN: 0254-9395 [Print] India
PMID2768883 (Publication Type: Journal Article)
Chemical References
  • Leprostatic Agents
Topics
  • Drug Therapy, Combination
  • Follow-Up Studies
  • Humans
  • Leprostatic Agents (administration & dosage, therapeutic use)
  • Leprosy, Borderline (drug therapy)
  • Leprosy, Tuberculoid (drug therapy)
  • Recurrence

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: